Timely drug delivery is the cornerstone of an effective healthcare infrastructure. Rising prevalence of chronic and infectious ailments have accelerated production of prescription drugs, prompting vendors to develop effective distribution networks.
Request a Sample to Obtain Authentic Analysis and Comprehensive Market Insights at- https://www.futuremarketinsights.com/reports/sample/rep-gb-12534
|Data Points||Market Insights|
|Market Value 2021||US$ 98.7 Mn|
|Market Value 2022||US$ 117.2 Mn|
|Market Value 2030||US$ 434.3 Mn|
|Market Share of Top 5 Countries||55.3%|
|Key Market Players||Wal-Mart Stores, Inc, Walgreen Co., Wal-Mart Stores, Inc., CVS Health, Express Scripts Holding Company, Giant Eagle, Inc., DocMorris (Zur Rose Group AG), Rowlands Pharmacy, OptumRx, Inc., Ali Health, Kroger Co. and Amazon (PillPack)|
Furthermore, advanced Prescription Delivery Systems have not only assisted in providing round-the-clock customer services but also helped manage dosage, therapy adherence and provide feedback to clinicians.
Advancements in consumer touch points and supply chains, including e-commerce, convenience stores and retail stores have greatly altered the prescription delivery services landscape. Advancements such as drone-based delivery and tracker based prescriptions are helping usher in smooth customer experience.
Prescription Delivery Services Market- Key Takeaways
- Diabetic prescription drugs to hold major sway, poised to capture 36.7% market share by 2030
- Ease of access to drugs addressing chronic conditions is slated to drive retail pharmacy growth to greater heights
- North America to expand stupendously at a CAGR of 18.4% from 2020-2030, attributed to the presence of multiple convenience and pharmacy stores
- Global prescription delivery services market to reach US$ 434.3 Mn by 2030-end
“Adoption of self-checkout kiosks and medicine dispensing machines shall enhance medicine purchasing experience of customers, permitting vendors to experience greater customer loyalty,” concludes the FMI analyst.
COVID-19 Impact Insights
The COVID-19 pandemic has generated fertile ground for the prescription delivery services market. The imposition of nationwide lockdowns to enforce social distancing have reduced footfalls across conventional pharmacies. This has compelled patients to rely on online retail platforms to avail their medicines.
Furthermore, heightened vulnerability of geriatrics suffering from co-morbidities to the coronavirus has necessitated stockpiling of essential medicines, thus keeping the need for prescription delivery services afloat throughout the pandemic’s duration. This panic buying behavior shall usher in an 80% y-o-y growth.
Growth is especially anticipated to be robust across the U.S, China and India, countries with the highest rates of infections. Collectively accounting for 40% of the global infection rate, these countries have witnessed an unprecedented increase in hoarding prescription medicines by individual households. This shall continue until the latter-half of 2021.
Market Witnessing Entry of e-Commerce Players
The Prescription Delivery Service Market is witnessing entry of e-Commerce, pharmacy and retail chains, albeit at a local or regional level. Technological developments, new product launches and collaborations characterize some critical expansion strategies of market players.
Some of the key players in the Prescription Delivery Service Market are: Walgreens Co., Walmart Stores Inc., CVS Health, Giant Eagle Inc., Express Scripts Holding Company, Ali Health and Kroger Co. to name a few.
Besides these established players, several startup companies are also emerging as potential game changers in the industry. These include NetMeds, Kfyao, Capsule, Myra Medicines, NURX, MedAvail, Zipdrug, Insightfil and ScriptDrop to name a few.
Walgreens, a prominent retail pharmaceutical distributor, has a robust presence in the global prescription delivery services market. The company offers refills, auto refills, drug information and home delivery services.
In 2017, the company acquired Rite Aid for a sum of US$ 5.2 billion, resulting in the merger of two of the United States’ three largest pharmacy chains.
Contact Sales for Further Assistance in Purchasing This Report- https://www.futuremarketinsights.com/checkout/12534